P/E ratio for Assertio Therapeutics (ASRT)
P/E ratio as of April 2024 (TTM): 0.4113
According to Assertio Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.4113. At the end of 2022 the company had a P/E ratio of 1.88.
P/E ratio history for Assertio Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 1.88 | -101.72% |
| 2021 | -109 | 3760.42% |
| 2020 | -2.82 | 584.42% |
| 2019 | -0.4125 | -106.63% |
| 2018 | 6.22 | -226.03% |
| 2017 | -4.94 | -60.53% |
| 2016 | -12.5 | -12.34% |
| 2015 | -14.3 | -299.38% |
| 2014 | 7.16 | -49.24% |
| 2013 | 14.1 | -223.06% |
| 2012 | -11.5 | -394.32% |
| 2011 | 3.89 | -95.1% |
| 2010 | 79.5 | -1120.45% |
| 2009 | -7.79 | 51.09% |
| 2008 | -5.16 | -258.17% |
| 2007 | 3.26 | -191.66% |
| 2006 | -3.56 | -62.06% |
| 2005 | -9.38 | 33.68% |
| 2004 | -7.01 | 23.64% |
| 2003 | -5.67 | 166.58% |
| 2002 | -2.13 | -43.88% |
| 2001 | -3.79 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.67 | -1,234.61% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -341.99% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.